Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Since the launch of the Crossword in 1942, The Times has captivated solvers by providing engaging word and logic games. In 2014, we introduced the Mini Crossword — followed by Spelling Bee, Letter ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Learn what a crypto wallet is and how to create one Manoj is a writer who ...

Dan Moskowitz is a financial writer who has 4+ years of experience creating content for the online reading market. Anthony Battle is a CERTIFIED FINANCIAL PLANNER™ professional. He earned the ...